Saadatian-Elahi Mitra, Rabilloud Muriel, Möhlmann Tim W R, Langlois-Jacques Carole, Ariffin Farah Diana, Farenhorst Marit, Elsensohn Mad-Hélénie, Schmitt Frédéric, Richardson Jason H, Baur Frédéric, Leduc Maxime, Romli Nurul Nadia, Tan Lay Kim, Norazman Mohd-Rosli, Shahar Hanipah, Mudin Rose Nani, Alexander Neal, Ab Hamid Nurulhusna
Service Hygiène, Epidémiologie, et Prévention, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Centre International de Recherche en Infectiologie, Team Public Health, Epidemiology, and Evolutionary Ecology of Infectious Diseases, Lyon, France.
Université Lyon 1, Lyon, France; Service de Biostatistique et Bio-informatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France; Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Lyon, France.
Lancet Infect Dis. 2025 Sep;25(9):977-985. doi: 10.1016/S1473-3099(25)00086-6. Epub 2025 May 12.
Malaysia is one of the southeast Asian countries hardest hit by dengue. We implemented a proactive integrated vector management (IVM) approach in a large non-blinded, cluster-randomised controlled trial to quantify its effectiveness on dengue incidence in urban settings.
In this cluster-randomised controlled trial we enrolled low-cost and medium-cost residential housing blocks in the Federal Territory of Kuala Lumpur and Putrajaya with recurrent dengue outbreaks. Of the 329 eligible sites, 139 were randomly allocated to receive IVM measures (community engagement, targeted outdoor residual spraying using K-Othrine Polyzone, and deployment of autodissemination devices to target both larval and adult mosquitoes) and 141 received routine vector control activities, stratified by block housing cost. The primary outcome was the comparison of dengue incidence between the two groups using information provided by the national e-Dengue surveillance system. Routine vector control activities continued in both control and intervention sites. The trial was retrospectively registered (ISRCTN81915073).
Between Feb 10, 2020, and Sept 30, 2022, we carried out our IVM approach in the 139 randomly selected intervention sites. 903 834 individuals (447 149 intervention, 456 685 control) were living in the study areas. Dengue was reported in 1434 individuals in the intervention group (mean incidence per 100 person-years of 0·16 [SD 0·18]) compared with 1663 in the control group (0·18 [0·19; risk ratio 0·86, 95% CI 0·70-1·06; p=0·17). No adverse effects were reported.
Our study did not show an effect on the primary endpoint of the overall dengue incidence. Several factors such as substantial decrease in dengue incidence during the COVID-19 pandemic could have reduced the statistical power to detect significant differences between the two groups. Preventive and long-lasting approaches such as our IVM should be further tested to see if targeted interventions could help limit the number of cases in high-risk transmission areas.
Ministry of Health Malaysia, Fondation Innovation en Infectiologie, the Australian Government, UK International Development from the UK Government, Envu.
For the Malay translation of the abstract see Supplementary Materials section.
马来西亚是登革热疫情最严重的东南亚国家之一。我们在一项大型非盲法整群随机对照试验中实施了积极的综合病媒管理(IVM)方法,以量化其对城市地区登革热发病率的影响。
在这项整群随机对照试验中,我们纳入了吉隆坡联邦直辖区和布城反复出现登革热疫情的低成本和中等成本住宅小区。在329个符合条件的地点中,139个被随机分配接受IVM措施(社区参与、使用K-Othrine Polyzone进行有针对性的室外滞留喷洒,以及部署自动传播装置以针对幼虫和成虫蚊子),141个接受常规病媒控制活动,并按街区住房成本进行分层。主要结果是使用国家电子登革热监测系统提供的信息比较两组之间的登革热发病率。对照组和干预组均继续开展常规病媒控制活动。该试验进行了回顾性注册(ISRCTN81915073)。
在2020年2月10日至2022年9月30日期间,我们在139个随机选择的干预地点实施了IVM方法。903834人(447149人在干预组,456685人在对照组)居住在研究区域。干预组有1434人报告感染登革热(每100人年的平均发病率为0.16[标准差0.18]),而对照组为1663人(0.18[0.19];风险比0.86,95%置信区间[CI]0.70 - 1.06;p = 0.17)。未报告不良反应。
我们的研究未显示对总体登革热发病率这一主要终点有影响。COVID-19大流行期间登革热发病率大幅下降等几个因素可能降低了检测两组之间显著差异的统计效力。应进一步测试像我们的IVM这样的预防性和长效方法,以确定有针对性的干预措施是否有助于限制高风险传播地区的病例数量。
马来西亚卫生部、感染病学创新基金会、澳大利亚政府、英国政府的英国国际发展部、安万特公司。
摘要的马来语翻译见补充材料部分。